Treats mild/moderate type 1 Gaucher disease. ANDA 209821, held by Edenbridge Pharms. Miglustat.
As of Nov 16, 2026, ANDA 209821 (Yargesa), held by Edenbridge Pharms, was first approved by FDA on Aug 6, 2020, with 1 approved supplement and 0 published complete response letters.
YARGESA is a glucosylceramide synthase inhibitor indicated as monotherapy for treatment of adult patients with mild/moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option. 1.1 Type 1 Gaucher Disease YARGESA is indicated as monotherapy for the treatment of adult patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option (e.g. due to allergy, hypersensitivity, or poor venous access).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 6, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Yargesa100MG · capsule;oral | Miglustat | Rx |
| Feb 10, 2021 | Supplement 1Labeling · Standard review | Approved | None posted |
| Aug 6, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters